SITC Unveils 2026 Class of Fellows Honoring Cancer Immunotherapy Luminaries
SITC Announces the 2026 Class of Fellows
The Society for Immunotherapy of Cancer (SITC) has proudly revealed the 2026 Class of Fellows of the Academy of Immuno-Oncology (FAIO), recognizing distinguished leaders whose groundbreaking work has significantly influenced the realm of cancer immunotherapy. This prestigious class will be inducted during a formal ceremony at the SITC 2026 Annual Meeting, scheduled for November 4-8, 2026, in Phoenix, Arizona, as well as via virtual participation.
"Being elected to the Academy of Immuno-Oncology stands as one of the highest honors within our profession," expressed Dr. Leisha A. Emens, Chair of SITC's Executive Council. "The 2026 Fellows have revolutionized our understanding of cancer immunotherapy over their extensive careers through innovative research and mentorship. Their pioneering discoveries have not only enhanced clinical practices but also positively impacted patients' lives worldwide, laying the groundwork for future breakthroughs. SITC is privileged to acknowledge their remarkable accomplishments and welcome them into the Academy."
Introduction of the 2026 Class of Fellows
The following individuals have been designated as the 2026 Class of the Academy of Immuno-Oncology:
- - Mary (Nora) Disis, MD – University of Washington
- - Kristen Hege, MD – Independent Board of Directors Member
- - Rachel Humphrey, MD – Normunity, Inc.
- - John M. Kirkwood, MD – University of Pittsburgh and UPMC Hillman Cancer Center
- - Hans-Georg Rammensee, PhD – University of Tübingen
Founded by SITC, the Academy of Immuno-Oncology acknowledges those whose visionary leadership and scientific achievements have propelled cancer immunotherapy from an experimental domain to a significant component of cancer treatment modalities. The Academy not only celebrates the extraordinary contributions of its honorees but also serves to inspire the next generation of leaders in the field of immuno-oncology.
Nominations for the new class of Fellows are sought annually, with the nomination process for the 2027 Class of Fellows set to open in the spring of 2027.
About SITC
Established in 1984, the Society for Immunotherapy of Cancer (SITC) operates as a nonprofit association of medical professionals committed to enhancing the outcomes for cancer patients through advancements in cancer immunotherapy and tumor immunology. SITC comprises a diverse group of influential scientists, practitioners, healthcare professionals, government leaders, and industry experts from around the world. The organization aims to encourage scientific exchange and collaboration through educational initiatives, creating a future where the word "cure" for cancer patients becomes a reality. To discover more about SITC and its educational offerings, please visit sitcancer.org and follow SITC on various social media platforms including X, LinkedIn, Facebook, Instagram, and YouTube.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.